Primary system organ class Preferred term* | No. of subjects (%) | No. of subjects (%) | No. of subjects (%) |
---|---|---|---|
THC/CBD spray (n= 36) | |||
Psychiatric disorders | |||
Euphoric mood | 2 (6) | - | - |
Nervous system disorders | |||
Dizziness | 2 (6) | - | - |
Dizziness postural | 3 (8) | - | - |
Headache | 5 (14) | - | - |
Somnolence | 11 (31) | - | - |
Gastrointestinal disorders | |||
Nausea | 2 (6) | - | - |
Rifampicin ( n= 12 ) | THC/CBD spray and Rifampicin ( n= 12 ) | THC/CBD spray ( n= 12 ) | |
Nervous system disorders | |||
Dysgeusia | 1 (8) | 0 | 1 (8) |
Headache | 0 | 1 (8) | 1 (8) |
Somnolence | 0 | 0 | 2 (17) |
Ketoconazole ( n= 12 ) | THC/CBD spray and Ketoconazole ( n= 11 ) | THC/CBD spray ( n= 12 ) | |
Nervous system disorders | |||
Somnolence | 0 | 4 (36) | 4 (33) |
Dizziness | 0 | 3 (27) | 2 (17) |
Lethargy | 0 | 3 (27) | 0 |
Dysgeusia | 0 | 2 (18) | 0 |
Headache | 0 | 2 (18) | 0 |
Somnolence | 0 | 1 (9) | 1 (8) |
Psychiatric disorders | |||
Euphoric mood | 0 | 7 (64) | 0 |
Anxiety | 0 | 1 (9) | 1 (8) |
Disorientation | 0 | 1 (9) | 1 (8) |
Omeprazole ( n= 12 ) | THC/CBD spray and Omeprazole ( n= 12 ) | THC/CBD spray ( n= 12 ) | |
Nervous system disorders | |||
Dizziness | 0 | 3 (25) | 0 |
Dizziness postural | 0 | 0 | 2 (17) |
Headache | 1 (8) | 0 | 4 (33) |
Somnolence | 0 | 2 (17) | 5 (42) |
Gastrointestinal disorders | |||
Dry mouth | 0 | 2 (17) | 1 (8) |